SOHO State of the Art Update and Next Questions: IDH therapeutic targeting in AML Journal Article


Authors: DiNardo, C. D.; Stein, E. M.
Article Title: SOHO State of the Art Update and Next Questions: IDH therapeutic targeting in AML
Abstract: Mutations in isocitrate dehydrogenase isoform (IDH) 1 and 2 occur in approximately 25% of patients with acute myeloid leukemia (AML). These mutations lead to a block in myeloid differentiation and ultimately, to the development of AML. Inhibitors of mutant IDH1 and 2 have recently been approved by the US Food and Drug Administration and their use has led to clinical responses with prolonged duration of response. IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used. © 2018 Elsevier Inc.
Keywords: isocitrate dehydrogenase; acute myeloid leukemia; enasidenib; ivosidenib; beta-hydroxyglutarate
Journal Title: Clinical Lymphoma, Myeloma and Leukemia
Volume: 18
Issue: 12
ISSN: 2152-2650
Publisher: Elsevier Inc.  
Date Published: 2018-12-01
Start Page: 769
End Page: 772
Language: English
DOI: 10.1016/j.clml.2018.10.007
PUBMED: 30416011
PROVIDER: scopus
DOI/URL:
Notes: Review -- Export Date: 3 December 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Eytan Moshe Stein
    134 Stein